DONALD LEE ANDERSON
- Type
- Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry
- Where
- BANNING, CA
- NPI
- 1447362082
- Received
- $33,504 in 16 records, 2019 to 2025 ($22 general, $33,481 research)
- As principal investigator
- $10,506,052 of research payments to others in 838 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | Research payment | 1 | $10,534 |
| 2023 | Research payment | 3 | $15,428 |
| 2022 | General payment | 1 | $22 |
| 2022 | Research payment | 2 | $2,028 |
| 2019 | Research payment | 9 | $5,491 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Eli Lilly and Company | 8 | $32,190 | 2019–2024 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 7 | $1,291 | 2019 |
| Boston Scientific Corporation | 1 | $22 | 2022 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 15 | $33,481 |
| Food and Beverage | 1 | $22 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-09-24 | Eli Lilly and Company | $10,534 | Research payment | Cash or cash equivalent | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM | 2024 | |
| 2023-10-10 | Eli Lilly and Company | $14,975 | Research payment | Cash or cash equivalent | ASSESSMENT OF SAFETY AND EFFICACY OF SUBCUTANEOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2023 | |
| 2023-06-08 | Eli Lilly and Company | $153 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY AND EFFICACY OF SUBCUTANEOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2023 | |
| 2023-01-31 | Eli Lilly and Company | $300 | Research payment | In-kind items and services | A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | 2023 | |
| 2022-05-31 | Boston Scientific Corporation | $22 | Food and Beverage | In-kind items and services | LUX-Dx Insertable Cardiac Monitor Device, LUX-Dx_CRM | 2022 | |
| 2022-05-03 | Eli Lilly and Company | $1,361 | Research payment | In-kind items and services | A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS | 2022 | |
| 2022-04-29 | Eli Lilly and Company | $667 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2022 | |
| 2019-10-08 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $217 | Research payment | In-kind items and services | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERAB | 2019 | |
| 2019-10-08 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $142 | Research payment | In-kind items and services | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERAB | 2019 | |
| 2019-10-08 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $112 | Research payment | Cash or cash equivalent | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERAB | 2019 | |
| 2019-10-08 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $50 | Research payment | In-kind items and services | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERAB | 2019 | |
| 2019-10-08 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $50 | Research payment | In-kind items and services | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERAB | 2019 | |
| 2019-10-07 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $125 | Research payment | In-kind items and services | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERAB | 2019 | |
| 2019-10-06 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $593 | Research payment | In-kind items and services | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERAB | 2019 | |
| 2019-01-28 | Eli Lilly and Company | $1,700 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2019 | |
| 2019-01-07 | Eli Lilly and Company | $2,500 | Research payment | Cash or cash equivalent | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-18 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $14,790 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-12-11 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $35 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-12-11 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $21,987 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-12-08 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $60 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-12-05 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $1,775 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-11-14 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $30,234 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-11-14 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $105 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-10-27 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $9,681 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-10-17 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $36,948 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-10-17 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $315 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-10-06 | E.R. Squibb & Sons, L.L.C. | ANDERSON CLINICAL RESEARCH | $38,940 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Kar | 2025 |
| 2025-09-29 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $3,300 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-09-26 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $3,062 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-09-15 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $20,216 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-09-15 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $48,395 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-09-15 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $4,835 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-09-08 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ANDERSON CLINICAL RESEARCH | $11,290 | A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT | 2025 |
| 2025-09-04 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $15,960 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-09-02 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ANDERSON CLINICAL RESEARCH | $60 | A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT | 2025 |
| 2025-08-26 | E.R. Squibb & Sons, L.L.C. | ANDERSON CLINICAL RESEARCH | $1,437 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Kar | 2025 |
| 2025-08-25 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $60 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-08-25 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $142 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-08-25 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $183 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-08-25 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $232 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-08-25 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $366 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-08-18 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $385 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-08-18 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $60 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-08-18 | Sage Therapeutics, LLC | ELLIGO HEALTH RESEARCH INC | $1,800 | A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzhe | 2025 |
| 2025-08-15 | Eli Lilly and Company | CLINEDGE LLC | $2,045 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2025 |
| 2025-08-13 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $40,447 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-08-13 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $140 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-08-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ANDERSON CLINICAL RESEARCH | $7,382 | A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT | 2025 |
| 2025-07-28 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $60 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-07-23 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $53,023 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-07-23 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $240 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-07-22 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $8,981 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-07-14 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $3,550 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-07-07 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $3,955 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-06-30 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $3,062 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-06-13 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $57,188 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-06-13 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $2,070 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-06-02 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $11,279 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-05-21 | Biogen, Inc. | Elligo Health Research | $10,684 | Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previ | 2025 |
| 2025-05-19 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $183 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-05-16 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $43,469 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-05-16 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $105 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-05-12 | Eli Lilly and Company | ELLIGO HEALTH RESEARCH INC | $97,755 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM | 2025 |
| 2025-05-05 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $20,034 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-04-16 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $1,106 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-04-16 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $45,164 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-03-27 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $2,262 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-03-24 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $14,921 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-03-07 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $20,000 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-03-05 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CLINEDGE LLC | $3,370 | AN OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREA | 2025 |
| 2025-02-28 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $9,813 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-02-25 | Eli Lilly and Company | ANDERSON CLINICAL RESEARCH | $607 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2025 |
| 2025-02-18 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $22,814 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-02-14 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $182 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-02-12 | Eli Lilly and Company | ANDERSON CLINICAL RESEARCH | $931 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM | 2025 |
| 2025-02-03 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $5,880 | A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an | 2025 |
| 2025-01-29 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CLINEDGE LLC | $2,180 | AN OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREA | 2025 |
| 2025-01-29 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CLINEDGE LLC | $19,848 | AN OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREA | 2025 |
| 2025-01-23 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ELLIGO HEALTH RESEARCH INC DBA PREFERRED RESEARCH PARTNERS INC | $180 | A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJU | 2025 |
| 2025-01-21 | Eli Lilly and Company | ELLIGO HEALTH RESEARCH INC | $13,510 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2025 |
| 2025-01-14 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $600 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-01-14 | Axsome Therapeutics, Inc. | ANDERSON CLINICAL RESEARCH | $8,688 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-01-07 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ELLIGO HEALTH RESEARCH INC | $2,800 | A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT | 2025 |
| 2024-12-23 | Axsome Therapeutics, Inc. | Elligo Health Research, Inc. | $245 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-12-12 | Axsome Therapeutics, Inc. | Elligo Health Research, Inc. | $25,492 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-12-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ELLIGO HEALTH RESEARCH INC | $500 | A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT | 2024 |
| 2024-11-15 | Axsome Therapeutics, Inc. | Elligo Health Research, Inc. | $36,839 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-11-12 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ELLIGO HEALTH RESEARCH INC | $1,665 | A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT | 2024 |
| 2024-10-16 | Axsome Therapeutics, Inc. | Elligo Health Research, Inc. | $50,315 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-10-16 | Axsome Therapeutics, Inc. | Elligo Health Research, Inc. | $105 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-10-07 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ELLIGO HEALTH RESEARCH INC | $3,800 | A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT | 2024 |
| 2024-09-26 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $975 | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2024 |
| 2024-09-19 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ELLIGO HEALTH RESEARCH INC DBA PREFERRED RESEARCH PARTNERS INC | $4,825 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD | 2024 |
| 2024-09-11 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ELLIGO HEALTH RESEARCH INC | $19,350 | A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT | 2024 |
| 2024-09-10 | Axsome Therapeutics, Inc. | Elligo Health Research, Inc. | $595 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-09-10 | Axsome Therapeutics, Inc. | Elligo Health Research, Inc. | $52,559 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-08-14 | Axsome Therapeutics, Inc. | Elligo Health Research, Inc. | $553 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-08-14 | Axsome Therapeutics, Inc. | Elligo Health Research, Inc. | $48,767 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-07-16 | Axsome Therapeutics, Inc. | Elligo Health Research, Inc. | $55,328 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-07-11 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CLINEDGE LLC | $1,000 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD | 2024 |
| 2024-06-20 | Axsome Therapeutics, Inc. | Elligo Health Research, Inc. | $80,195 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-06-20 | Axsome Therapeutics, Inc. | Elligo Health Research, Inc. | $1,347 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-06-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ELLIGO HEALTH RESEARCH INC DBA PREFERRED RESEARCH PARTNERS INC | $7,734 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD | 2024 |
| 2024-06-04 | Eli Lilly and Company | ELLIGO HEALTH RESEARCH INC | $71,878 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2024 |
| 2024-06-03 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $3,650 | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2024 |
| 2024-05-30 | Otsuka Pharmaceutical Development & Commercialization, Inc. | CLINICAL TRIAL SOURCE LLC | $2,971 | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF FIXED-DOSE BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALIN | 2024 |
| 2024-05-16 | Axsome Therapeutics, Inc. | Elligo Health Research, Inc. | $455 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-05-16 | Axsome Therapeutics, Inc. | Elligo Health Research, Inc. | $81,275 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-05-16 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CLINEDGE LLC | $416 | AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT | 2024 |
| 2024-05-16 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CLINEDGE LLC | $416 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD | 2024 |
| 2024-05-01 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CLINEDGE LLC | $17,409 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD | 2024 |
| 2024-04-22 | Janssen Research & Development, LLC | ELLIGO HEALTH RESEARCH INC | $3,562 | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2024 |
| 2024-04-16 | Axsome Therapeutics, Inc. | Elligo Health Research, Inc. | $70 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-04-16 | Axsome Therapeutics, Inc. | Elligo Health Research, Inc. | $59,990 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-03-18 | Axsome Therapeutics, Inc. | Elligo Health Research, Inc. | $56,556 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-03-06 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CLINEDGE LLC | $5,267 | AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Banning, CA, county Riverside County, CA, state California; placed by its city name.
| Measure | Place (city or town) Banning, CA | County Riverside County, CA | State California |
|---|---|---|---|
| Population B01003 | 31,093 | 2,478,600 | 39,287,377 |
| Population, 2020 census P1 | 29,505 | 2,418,185 | 39,538,223 |
| Median age B01002 | 42.1 | 37.0 | 37.9 |
| Under 18 B01001 | 22.8% | 24.1% | 22.0% |
| 65 and over B01001 | 27.7% | 15.4% | 15.7% |
| Households B11001 | 11,624 | 775,335 | 13,548,091 |
| Foreign born B05002 | 18.7% | 21.9% | 27.0% |
| Median household income B19013 | $61,764 | $93,074 | $99,122 |
| Median family income B19113 | $64,695 | $103,984 | $113,346 |
| Per capita income B19301 | $30,856 | $38,317 | $49,513 |
| Poverty rate B17001 | 18.8% | 10.6% | 12.0% |
| Unemployment rate B23025 | 8.2% | 6.5% | 6.6% |
| Civilian labor force B23025 | 11,583 | 1,191,323 | 20,068,466 |
| Mean commute (minutes) B08013 | 32.6 | 33.8 | 28.7 |
| Bachelor's degree or higher B15003 | 16.5% | 25.6% | 37.1% |
| Housing units B25001 | 12,355 | 869,414 | 14,644,735 |
| Owner-occupied B25003 | 70.2% | 69.1% | 55.9% |
| Renters B25003 | 29.8% | 30.9% | 44.1% |
| Median home value B25077 | $352,100 | $557,300 | $734,700 |
| Median gross rent B25064 | $1,650 | $1,901 | $2,036 |
| White, not Hispanic B03002 | 33.3% | 31.0% | 33.8% |
| Black B03002 | 7.1% | 6.0% | 5.2% |
| Hispanic or Latino B03002 | 50.6% | 51.3% | 40.2% |
| Asian B03002 | 5.1% | 6.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.7% | 0.3% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Banning, CA.
Comments